Stock Analysis

ASX Growth Companies With High Insider Ownership And At Least 11% Revenue Growth

ASX:BOT
Source: Shutterstock

Amidst a somewhat directionless Australian market, with the ASX200 showing minimal movement and commodities experiencing varied trends, investors continue to seek opportunities that stand out from broader market fluctuations. In this context, growth companies with high insider ownership can be particularly appealing as they often signal strong confidence from those closest to the company’s operations and future prospects.

Top 10 Growth Companies With High Insider Ownership In Australia

NameInsider OwnershipEarnings Growth
Hartshead Resources (ASX:HHR)13.9%86.3%
Cettire (ASX:CTT)28.7%30.1%
Acrux (ASX:ACR)14.6%115.3%
Doctor Care Anywhere Group (ASX:DOC)28.4%96.4%
Plenti Group (ASX:PLT)12.8%106.4%
Hillgrove Resources (ASX:HGO)10.4%45.4%
Change Financial (ASX:CCA)26.6%85.4%
Botanix Pharmaceuticals (ASX:BOT)11.4%120.9%
Liontown Resources (ASX:LTR)16.4%63.9%
SiteMinder (ASX:SDR)11.3%72.7%

Click here to see the full list of 91 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Botanix Pharmaceuticals (ASX:BOT)

Simply Wall St Growth Rating: ★★★★★★

Overview: Botanix Pharmaceuticals Limited, based in Australia, focuses on the research and development of dermatology and antimicrobial products with a market capitalization of approximately A$519.80 million.

Operations: The company generates revenue primarily from its research and development activities in dermatology and antimicrobial products, totaling approximately A$0.44 million.

Insider Ownership: 11.4%

Revenue Growth Forecast: 120.4% p.a.

Botanix Pharmaceuticals, with a modest A$437K in revenue, is poised for significant expansion. The company's Return on Equity is expected to be very high at 43.9% in three years, complemented by a projected annual earnings growth rate of 120.89%. Despite these promising figures, Botanix faces challenges such as less than one year of cash runway and recent shareholder dilution. On May 6, 2024, the firm discussed its commercial launch plans for SofdraÔ as it nears approval.

ASX:BOT Ownership Breakdown as at Jun 2024
ASX:BOT Ownership Breakdown as at Jun 2024

Capricorn Metals (ASX:CMM)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Capricorn Metals Ltd is an Australian company focused on the evaluation, exploration, development, and production of gold properties, with a market capitalization of approximately A$1.77 billion.

Operations: The company generates revenue primarily from its Karlawinda segment, totaling approximately A$356.94 million.

Insider Ownership: 12.3%

Revenue Growth Forecast: 14.1% p.a.

Capricorn Metals is set to outpace the Australian market with its revenue and earnings growth forecasted at 14.1% and 26.5% per year, respectively. Despite a lack of recent insider buying and significant one-off items affecting its financial results, the company's Return on Equity is expected to reach a high of 30.6% in three years. However, it faces challenges as profit margins have decreased from last year's 25.4% to just 5.2%.

ASX:CMM Earnings and Revenue Growth as at Jun 2024
ASX:CMM Earnings and Revenue Growth as at Jun 2024

Technology One (ASX:TNE)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Technology One Limited is an Australian company that develops, markets, sells, implements, and supports integrated enterprise business software solutions both domestically and internationally, with a market capitalization of A$5.97 billion.

Operations: The company generates revenue through three primary segments: software sales contributing A$317.24 million, corporate services at A$83.83 million, and consulting services totaling A$68.13 million.

Insider Ownership: 12.3%

Revenue Growth Forecast: 11.1% p.a.

Technology One, an Australian software company, shows promise with its insider ownership structure supporting a growth narrative. The company's revenue and earnings are forecasted to grow at 11.1% and 14.3% per year respectively, outpacing the broader Australian market rates of 5.4% and 13.7%. Although this growth is robust, it does not reach the high-growth benchmark of over 20%. Recent financials underscore this trajectory with a reported increase in half-year revenue to A$240.83 million from A$201.01 million year-on-year and net income rising to A$48 million from A$41.28 million.

ASX:TNE Earnings and Revenue Growth as at Jun 2024
ASX:TNE Earnings and Revenue Growth as at Jun 2024

Key Takeaways

Contemplating Other Strategies?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Valuation is complex, but we're helping make it simple.

Find out whether Botanix Pharmaceuticals is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com